Literature DB >> 20112365

Effect of interleukin-32gamma on differentiation of osteoclasts from CD14+ monocytes.

Yong-Gil Kim1, Chang-Keun Lee, Ji Seon Oh, Soo-Hyun Kim, Kyoung-A Kim, Bin Yoo.   

Abstract

OBJECTIVE: Interleukin-32 (IL-32) induces various inflammatory molecules in human monocytes and differentiation of monocytes into macrophage-like cells. This study was undertaken to evaluate the effects of IL-32gamma, the most biologically active isoform, on the differentiation and activation of osteoclasts.
METHODS: CD14+ monocytes were obtained from healthy volunteers, and samples of synovial tissue and synovial fluid were obtained from patients with rheumatoid arthritis (RA) and patients with osteoarthritis (OA). The concentration and expression levels of IL-32gamma in RA and OA samples were evaluated by enzyme-linked immunosorbent assay and immunoblotting, respectively. To examine the osteoclastogenic effects and functional activities, isolated monocytes were treated with either IL-32gamma or IL-17 in the presence or absence of soluble RANKL (sRANKL) on a culture system and on Osteologic disks. The expression of RANKL and osteoprotegerin (OPG) messenger RNA (mRNA) in RA fibroblast-like synoviocytes (FLS) was measured using reverse transcription-polymerase chain reaction (PCR) and real-time PCR.
RESULTS: The concentration and expression levels of IL-32gamma were higher in the RA samples than in the OA samples. Upon costimulation with sRANKL, the osteoclast count and resorbed area increased more significantly in the IL-32gamma-stimulated cultures than in those stimulated with IL-17. In the IL-32gamma-treated group without sRANKL stimulation, osteoclasts were differentiated, but the cells displayed low resorption activity. In RA FLS, RANKL mRNA expression increased in the presence of both IL-32gamma and IL-17. However, transcription of OPG decreased following IL-32gamma stimulation, resulting in a significant increase in the RANKL:OPG ratio.
CONCLUSION: Our results suggest that IL-32gamma is a potent mediator of active osteoclast generation in the presence of sRANKL. Moreover, this novel cytokine creates more favorable conditions for osteoclastogenesis in the RA joint by increasing the RANKL:OPG ratio in FLS.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20112365     DOI: 10.1002/art.27197

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  26 in total

1.  The influence of interleukin-32γ on osteoclastogenesis with a focus on fusion-related genes.

Authors:  Yong-Gil Kim; Min Wook So; Bon San Koo; Eun-Ju Chang; Seok Jong Song; Chang-Keun Lee; Bin Yoo
Journal:  J Clin Immunol       Date:  2011-11-09       Impact factor: 8.317

2.  Interleukin-32gamma enhances the production of IL-6 and IL-8 in fibroblast-like synoviocytes via Erk1/2 activation.

Authors:  Yong-Gil Kim; Chang-Keun Lee; Soo-Hyun Kim; Woo-Shin Cho; Se Hwan Mun; Bin Yoo
Journal:  J Clin Immunol       Date:  2010-01-14       Impact factor: 8.317

3.  Dissection of the cord blood stromal component reveals predictive parameters for culture outcome.

Authors:  Mario Barilani; Cristiana Lavazza; Mariele Viganò; Tiziana Montemurro; Valentina Boldrin; Valentina Parazzi; Elisa Montelatici; Mariacristina Crosti; Monica Moro; Rosaria Giordano; Lorenza Lazzari
Journal:  Stem Cells Dev       Date:  2015-01-01       Impact factor: 3.272

4.  Interleukin 32 (IL-32) contains a typical α-helix bundle structure that resembles focal adhesion targeting region of focal adhesion kinase-1.

Authors:  Bas Heinhuis; Marije I Koenders; Wim B van den Berg; Mihai G Netea; Charles A Dinarello; Leo A B Joosten
Journal:  J Biol Chem       Date:  2011-12-27       Impact factor: 5.157

5.  Hypoxia promotes IL-32 expression in myeloma cells, and high expression is associated with poor survival and bone loss.

Authors:  Muhammad Zahoor; Marita Westhrin; Kristin Roseth Aass; Siv Helen Moen; Kristine Misund; Katarzyna Maria Psonka-Antonczyk; Mariaserena Giliberto; Glenn Buene; Anders Sundan; Anders Waage; Anne-Marit Sponaas; Therese Standal
Journal:  Blood Adv       Date:  2017-12-13

6.  IL-32 aggravates synovial inflammation and bone destruction and increases synovial natural killer cells in experimental arthritis models.

Authors:  Young-Eun Park; Geun-Tae Kim; Seung-Geun Lee; Seong-Hu Park; Seung-Hoon Baek; Sung-Il Kim; Ju-In Kim; Hua-Shu Jin
Journal:  Rheumatol Int       Date:  2012-04-19       Impact factor: 2.631

Review 7.  Induction of osteoclast progenitors in inflammatory conditions: key to bone destruction in arthritis.

Authors:  Alan Sućur; Vedran Katavić; Tomislav Kelava; Zrinka Jajić; Natasa Kovačić; Danka Grčević
Journal:  Int Orthop       Date:  2014-06-10       Impact factor: 3.075

8.  Osteoclast fusion and regulation by RANKL-dependent and independent factors.

Authors:  Lianping Xing; Yan Xiu; Brendan F Boyce
Journal:  World J Orthop       Date:  2012-12-18

Review 9.  Novel insights into the biology of interleukin-32.

Authors:  Leo A B Joosten; Bas Heinhuis; Mihai G Netea; Charles A Dinarello
Journal:  Cell Mol Life Sci       Date:  2013-03-06       Impact factor: 9.261

Review 10.  The dynamic evolution of rheumatology in Korea.

Authors:  Ho-Youn Kim; Yeong-Wook Song
Journal:  Nat Rev Rheumatol       Date:  2015-12-17       Impact factor: 20.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.